Introduction: Type 2 diabetes mellitus (T2DM) is increasingly prevalent and associated with increased morbi/mortality. In Caucasian obese subjects we investigated a possible link between 1-hour plasma glucose (1HrPG), diabetes and the metabolic syndrome (MetS).

Methods: Overweight and obese patients were consecutively included from the obesity clinic. ROC-curves were used to compare the diagnostic sensitivity and specificity of 1HrPG vs. fasting plasma glucose (FPG), 2HrPG, and HbA1c to diagnose diabetes, using American Diabetes Association criteria.

Results: We included 2439 patients (72% female) [mean age 43±13 years, median BMI 37.3 (33.7-41.3) kg/m²]. Diabetes was diagnosed in 9.8% and prediabetes in 33.8% of subjects. Exactly 1262 (51,7%) had a 1HrPG ≥155 mg/dL. These subjects were more insulin-resistant (p<0.001), had a higher waist (p<0.001), visceral adipose tissue (VAT) (p<0.001), systolic blood pressure (p<0.001), worse lipid profile (p<0.001), and higher plasminogen activator inhibitor-1 (PAI-1) [p<0.001] than subjects with 1HrPG <155mg/dL. MetS was present in 64.1% of the subjects with 1HrPG ≥155 mg/dL vs. 42.5% of subjects with a 1HrPG <155 mg/dL (p<0.001). In the group with 1HrPG ≥155 mg/dL only 32.6% had a normal glucose tolerance (NGT) while 18.5% was diagnosed with T2DM and 48.9% had prediabetes, compared to 81.7% NGT, 0.6% T2DM and 17.7% prediabetes in subjects with a 1HrPG < 155 mg/dL (p<0.001). In the group with NGT 412 subjects (30,0%) had a 1HrPG ≥155 mg/dL. These subjects showed higher HOMA-IR (p=0.008), VAT (p<0.001), blood pressure (p<0.001), worse lipid profile (p=0.001) than those with a 1HrPG<155 mg/dl, indicating its clinical relevance. For diabetes, the ROC area under the curve for 2HrPG was 0.928, compared to 1HrPG (0.764), Hba1c (0.752) and, FPG (0.600).

Conclusion: This study supports the need for detection of subjects with higher 1HrPG values. being at risk for development of T2DM, MetS and cardiovascular disease.

Disclosure

L. Haverals: None. K.P.S. Van Dessel: None. A. Verrijken: None. E.L. Dirinck: None. F.W. Peiffer: None. L. Van Gaal: Advisory Panel; Self; Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen J & J, Merck MSD, Novo Nordisk, Sanofi and Servier/Intarcia. Speaker's Bureau; Self; Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen J & J, Merck MSD, Novo Nordisk, Sanofi and Servier/Intarcia. Research Support; Self; EU (Hepadip & Resolve consortium) and National Research Funds. C. De Block: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.